Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan

被引:0
作者
Yukie Omori
Sotaro Enatsu
Zhihong Cai
Hiroshi Ishiguro
机构
[1] Eli Lilly Japan K.K.,
[2] Medicines Development Unit Japan,undefined
[3] Eli Lilly Japan K.K.,undefined
[4] Medicines Development Unit Japan,undefined
[5] International University of Health and Welfare Hospital,undefined
来源
Breast Cancer | 2019年 / 26卷
关键词
Breast cancer; Patient preference; Cyclin-dependent kinase 4; Cyclin-dependent kinase 6;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:652 / 662
页数:10
相关论文
共 120 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Ferlay J(2005)Comparison of breast cancer mortality in five countries: France, Italy, Japan, the UK and the USA from the WHO mortality database (1960–2000) Jpn J Clin Oncol 35 758-759
[3]  
Soerjomataram I(2016)Past trends and future estimation of annual breast cancer incidence in Osaka, Japan Asian Pac J Cancer Prev 17 2847-2852
[4]  
Siegel RL(2009)Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study Am J Epidemiol 169 1251-1259
[5]  
Torre LA(2015)Mechanisms of hormonal therapy resistance in breast cancer Int J Clin Oncol 20 262-267
[6]  
Jemal A(2014)ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Ann Oncol 25 1871-1888
[7]  
Kawamura T(2018)Recent advances in the treatment of breast cancer Front Oncol 8 227-529
[8]  
Sobue T(2012)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 520-e953
[9]  
Toyoda Y(2018)CDK4/6 inhibition in breast cancer: current practice and future directions Ther Adv Med Oncol 10 1758835918786451-107
[10]  
Tabuchi T(2018)CDK4/6 inhibitors in combination with hormone therapy for HR(+)/HER2() advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials Clin Breast Cancer 18 e943-4429